Efficacy and Safety of Rilpivirine (TMC278) Versus Efavirenz at 48 Weeks in Treatment-Naive HIV-1–Infected Patients
Authors:
- Calvin J. CohenCCCalvin J. Cohen
- Jean-Michel MolinaJMJean-Michel Molina
- Pedro CahnPCPedro Cahn
- Bonaventura ClotetBCBonaventura Clotet
- Jan FourieJFJan Fourie
- Beatriz GrinsztejnBGBeatriz Grinsztejn
- Hao WuHWHao Wu
- Margaret A. JohnsonMJMargaret A. Johnson
- Michael SaagMSMichael Saag
- Khuanchai SupparatpinyoKSKhuanchai Supparatpinyo
- Herta CrauwelsHCHerta Crauwels
- Eric LefebvreELEric Lefebvre
- 1 May 2012
- journal article
- research article
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 60 (1) , 33-42
Abstract
Pooled analysis of phase 3, double-blind, double-dummy ECHO and THRIVE trials comparing rilpivirine (TMC278) and efavirenz. Treatment-naive HIV-1-infected adults were randomized 1:1 to rilpivirine 25 mg once daily or efavirenz 600 mg once daily, with background tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) (ECHO) or TDF/FTC, zidovudine/lamivudine, or abacavir/lamivudine (THRIVE). The primary endpoint was confirmed response [viral load <50 copies per milliliter; intent-to-treat time-to-loss-of-virologic-response (ITT-TLOVR) algorithm] at week 48. The pooled data set enabled analyses of subgroups and predictors of response/virologic failure. Confirmed responses were 84% (rilpivirine) and 82% (efavirenz). The difference in response rates (95% confidence interval) was 2.0% (-2.0% to 6.0%). The incidence of virologic failure was 9% (rilpivirine) versus 5% (efavirenz). Responses in ITT-TLOVR and ITT-snapshot analyses were consistent. Responses were similar for rilpivirine and efavirenz by background regimen, gender, race and clade. Suboptimal adherence and higher baseline viral load resulted in lower responses, higher virologic failure, and development of resistance in both groups; the effects on virologic failure were more apparent with rilpivirine. CD4 cell count increased over time in both groups. Rilpivirine compared with efavirenz gave smaller incidences of adverse events leading to discontinuation (3% vs. 8%, respectively), treatment-related grade 2-4 adverse events (16% vs. 31%), rash (3% vs. 14%), dizziness (8% vs. 26%), abnormal dreams/nightmares (8% vs. 13%), and grade 2-4 lipid abnormalities. At week 48, rilpivirine 25 mg once daily and efavirenz 600 mg once daily had comparable response rates. Rilpivirine had more virologic failures and improved tolerability versus efavirenz.Keywords
This publication has 22 references indexed in Scilit:
- The HIV-1 Reverse Transcriptase M184I Mutation Enhances the E138K-Associated Resistance to Rilpivirine and Decreases Viral FitnessJAIDS Journal of Acquired Immune Deficiency Syndromes, 2012
- Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trialThe Lancet, 2011
- Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trialThe Lancet, 2011
- Potent Inhibition of Human Enterovirus 71 Replication by Type I Interferon SubtypesAntiviral Therapy, 2011
- TMC278, a Next-Generation Nonnucleoside Reverse Transcriptase Inhibitor (NNRTI), Active against Wild-Type and NNRTI-Resistant HIV-1Antimicrobial Agents and Chemotherapy, 2010
- Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trialAIDS, 2010
- Simple Adherence Assessments to Predict Virologic Failure among HIV-Infected Adults with Discordant Immunologic and Clinical Responses to Antiretroviral TherapyAIDS Research and Human Retroviruses, 2008
- Abacavir versus Zidovudine Combined with Lamivudine and Efavirenz, for the Treatment of Antiretroviral‐Naive HIV‐Infected AdultsClinical Infectious Diseases, 2004
- Once-Daily versus Twice-Daily Lamivudine, in Combination with Zidovudine and Efavirenz, for the Treatment of Antiretroviral-Naive Adults with HIV Infection: A Randomized Equivalence TrialClinical Infectious Diseases, 2004
- Virologic Outcome and Predictors of Virologic Failure of Highly Active Antiretroviral Therapy Containing Protease InhibitorsAIDS Patient Care and STDs, 2001